dInfant botulism is a potentially life-threatening paralytic disease that can be associated with prolonged morbidity if not rapidly diagnosed and treated. Four infants were diagnosed and treated for infant botulism in NSW, Australia, between May 2011 and August 2013. Despite the temporal relationship between the cases, there was no close geographical clustering or other epidemiological links. Clostridium botulinum isolates, three of which produced botulism neurotoxin serotype A (BoNT/A) and one BoNT serotype B (BoNT/B), were characterized using whole-genome sequencing (WGS). In silico multilocus sequence typing (MLST) found that two of the BoNT/A-producing isolates shared an identical novel sequence type, ST84. The other two isolates were single-locus variants of this sequence type (ST85 and ST86). All BoNT/A-producing isolates contained the same chromosomally integrated BoNT/A2 neurotoxin gene cluster. The BoNT/B-producing isolate carried a single plasmid-borne bont/B gene cluster, encoding BoNT subtype B6. Single nucleotide polymorphism (SNP)-based typing results corresponded well with MLST; however, the extra resolution provided by the whole-genome SNP comparisons showed that the isolates differed from each other by >3,500 SNPs. WGS analyses indicated that the four infant botulism cases were caused by genomically distinct strains of C. botulinum that were unlikely to have originated from a common environmental source. The isolates did, however, cluster together, compared with international isolates, suggesting that C. botulinum from environmental reservoirs throughout NSW have descended from a common ancestor. Analyses showed that the high resolution of WGS provided important phylogenetic information that would not be captured by standard seven-loci MLST.
Genomic epidemiology has provided novel insights into the genetic characteristics and phylogenetic diversity of botulinum neurotoxin (BoNT)-producing Clostridium species (1-8).BoNT subtypes are responsible for causing the serious paralytic disease botulism and their potent neuroparalytic activities make them one of the top (tier 1) agents considered to pose a significant threat to public health if used for bioterrorism (Electronic Code of Federal Regulations-Title 42: Part 73; http://www.ecfr.gov/cgi -bin/retrieveECFR?rϭPART&nϭ42y1.0.1.6.61) (9, 10). The same properties also make them powerful tools for both medical therapeutic and cosmetic applications (11).Botulism is a very rare disease in Australia (National Notifiable Diseases Surveillance System [NNDSS]; http://www9.health.gov .au/cda/source/cda-index.cfm), with only 20 cases reported since 1991. However, a global survey found that Australia had one of the highest numbers of notified cases of infant botulism in the world (12, 13). Infant botulism results from the ingestion of Clostridium botulinum spores which germinate and temporarily colonize the infant's colon, followed by growth of vegetative cells that produce . This form of the disease only occurs in infants, generally under 1 year old, as they h...